Author Affiliation: National Heart, Lung, and Blood Institute, Bethesda, Md.
Treatment of coronary heart disease (CHD), the leading cause of mortality
in the United States, has progressed significantly over the past several decades.
As new approaches have emerged and become accepted forms of therapy, CHD mortality
has steadily decreased. Coronary revascularization by percutaneous coronary
intervention (PCI) can provide relief of symptoms and ischemia in patients
with CHD by reducing luminal obstruction and improving coronary flow. Since
the first percutaneous transluminal coronary angioplasty (PTCA) performed
in 1977, the number of PCIs has increased dramatically, with more than 600 000
now performed annually in the United States.1
Despite significant improvements in PCI technology, restenosis remains the
major limitation of percutaneous revascularization techniques, with peak occurrence
1 to 3 months following successful dilation. Restenosis rates vary widely
depending on the technique, ranging from nearly 0% with sirolimus stents2 and less than 10% with brachytherapy3
to as high as 60% in some studies.4
Sopko G. Preventing Cardiac Events and Restenosis After Percutaneous Coronary Intervention. JAMA. 2002;287(24):3259-3261. doi:10.1001/jama.287.24.3259